A.S. Gardberg

Ability of Bruton’s Tyrosine Kinase Inhibitors to Sequester Y551 and Prevent Phosphorylation Determines Potency for Inhibition of Fc Receptor but not B-Cell Receptor Signaling

Andrew T. Bender, A.S. Gardberg, Albertina Pereira et al. · Molecular Pharmacology · 2017 · 188 citations

Life Sciences, Immunology, Pharmacology +17

Discovery of Evobrutinib: An Oral, Potent, and Highly Selective, Covalent Bruton’s Tyrosine Kinase (BTK) Inhibitor for the Treatment of Immunological Diseases

Richard D. Caldwell, Hui Qiu, Ben Askew et al. · Journal of Medicinal Chemistry · 2019 · 140 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +14

Increasing the structural coverage of tuberculosis drug targets

Loren Baugh, Isabelle Phan, Darren W. Begley et al. · Tuberculosis · 2014 · 130 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +13

Combining Functional and Structural Genomics to Sample the Essential Burkholderia Structome

Loren Baugh, Larry A. Gallagher, Rapatbhorn Patrapuvich et al. · PLoS ONE · 2013 · 129 citations · Full text

Life Sciences, Microbiology, Molecular Biology +17

Molecular basis for passive immunotherapy of Alzheimer's disease

A.S. Gardberg, Lezlee Dice, Susan Ou et al. · Proceedings of the National Academy of Sciences · 2007 · 109 citations · Full text

Life Sciences, Biochemistry, Molecular Biology +17